Media

Media

Recent News

  • Avivagen Director Aubrey Dan Named Member of the Order of Canada

    Ottawa, ON and Toronto, ON / Business Wire / July 23, 2019/ Avivagen (TSXV:VIV) (“Avivagen” or the Corporation), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, is pleased to announce that Mr. Aubrey Dan has been named a Member of the Order of …Read More

  • Avivagen and Mimi’s Rock Announce Joint Venture for the Companion Animal Market

    State of the art e-commerce platform to offer exclusive products for the pet market Ottawa, ON and Toronto, ON / Business Wire / June 13, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), owner of the intellectual property protected OxC-beta™ technology that supports the optimal health of companion animals, and Mimi’s Rock Corp. …Read More

  • Avivagen Inc. Announces Results for the Second Quarter Ending April 30, 2019

    An increase of 73% in sales over the six-month period Ottawa, ON /Business Wire/ June 4, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a world leader in natural alternatives to antibiotics with its OXC-beta™ technology, reported today its unaudited financial results for the second quarter of 2019 and Stock Option plan update. …Read More

  • Avivagen Announces Officer Changes

    Ottawa, ON / Business Wire / May 14, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, announces the appointments of Mr. Kym Anthony to the position …Read More

  • Avivagen Press Release Correction

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. Ottawa, ON/Business Wire/April 12, 2019/Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human …Read More

View All News Releases

Media Coverage

  • VICTAM Asia

    Avivagen CEO Interviewed at VICTAM Asia 2018 Conference

    Avivagen recently debuted at the VICTAM ASIA 2018 Conference in Bangkok, Thailand.

  • CEO Kym Anthony Interviewed by Uptick

    CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.

    I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.

  • CTV: Growing resistance to antibiotics fuels market for alternative solutions

    CTV NEWS, TORONTO – A hundred years ago, a small wound could result in death if an infection spread. That could become reality again as the world threatens to return to a pre-antibiotic era due to antibiotic resistance.

    Some have pointed to the widespread use of antibiotics in livestock feed as a culprit, resulting in urgent calls to quell their use and find alternatives.

View All Media Coverage